Pharmaceutical & Biotech News and Insights

Big Pharma Advertising
The most common mode of advertising for Big Pharma companies remains to be television. With the increased presence of social media, digital and mobile advertising, ... 
Read More


IMS report: Cancer drug spending increases to $100B
New IMS numbers show that global spending on cancer therapies have increased $75 billion in just the last 5 years with a 10.3% increase in ... 
Read More


Mylan rejects Teva’s offer
Mylan has rejected a $40 billion offer from Teva to become the industry's biggest generic drug company. The reasoning behind the rejection was Mylan felt ... 
Read More


Good news for GW Pharmaceutical’s epilepsy drug
New data from a Phase III study of GW Pharmaceuticals' in-development epilepsy drug shows a reduction the rates of seizures by more than 50%. The ... 
Read More


Teva to buy Auspex
Teva announced that they have entered into a definitive merger agreement with Auspex Pharmaceuticals. Teva will pay $101 per share, or about $3.2 billion for ... 
Read More


New Alzheimer's R&D project
With the number of people with dementia expected to triple by 2050, several industry giants are investing in a $100 million effort to find effective ... 
Read More


Astellas awarded FDA approval
Astellas was awarded FDA approval for Cresemba, an antifungal treatment for two rare but dangerous infections that commonly affect patients undergoing chemotherapy or who have ... 
Read More


Supply switch causing delays and cost changes for Genentech’ cancer drugs
A recent survey conducted by a hospital services company, Novation, has shown that since Genentech moved its best-selling cancer drugs to specialty distributors there have ... 
Read More


Baxter Picks HQ Location for its Biopharma Spinoff
Baxalta Incorporated, will set up shop in a 260,000 square foot building located in Bannockburn, IL, a short 6 mile trip up the road from ... 
Read More


Eisai gets an early FDA Approval
The FDA as awarded an early approval to Eisai for its new thyroid cancer drug. Lenvatinib, which will sell as Lenvima blocks the growth agent ... 
Read More


« prev - page 1 of 3 - next »